Science News

Roche Announced Patient Program for TASMAR Users

- Feb 03 2000

Patients who are continuing to use TASMAR, the COMT inhibitor that was linked last year to a rare complication of liver failure, are invited to join a new Liver Enzyme Monitoring Program sponsored by the manufacturer, Hoffmann-La Roche, Inc. Dr. William Lief, TASMAR's product director, said that the program was designed to help "learn as much as we can about how TASMAR can be used with the highest possible safety margin."

For a copy of the one-page application form, call Shelley Rosenstock at (973) 562-2373.

Source Date: Feb 03 2000